FDA Approves Olaparib, a PARP Inhibitor, for BRCA+ Breast CancerJanuary 12th 2018
Based on results from the phase III OlympiAD trial, the FDA approved olaparib (Lynparza), a PARP inhibitor, for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. HR-positive patients must also have had prior endocrine therapy.
Investigating the Use of Olaparib and Durvalumab in BRCA-mutant Breast Cancer TreatmentDecember 28th 2017
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) for pretreated patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer shows great promise for future treatment.
For Women With BRCA Mutations, Who Is Most at Risk of Breast and Ovarian Cancer?June 26th 2017
A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.
BRCA Gene Does Not Worsen Prognosis in Patients with Breast CancerJanuary 5th 2017
A recent study found that young women with breast cancer who are BRCA-positive have similar, or better, outcomes than those who do not, and that preventative bilateral mastectomy in this population does not improve the risk for recurrence or death.
Cathy Belt on How to Act on Inherited Cancer SymptomsSeptember 14th 2016
Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.
Identifying Patients and Families at Risk for CancerAugust 22nd 2016
With approximately 5% to 10% of cancers attributable to a hereditary cancer predisposition syndrome, identifying those patients with cancer who are at risk has significant benefit both to patients and their relatives.
Women Need More Information to Cope With Aftermath of BRCA-Prompted Preventive SurgeryAugust 1st 2016
A study involving women with a BRCA mutation who had risk-reducing surgery to lower their risk of breast and/or ovarian cancer found that many of these individuals have surgical procedures such as oophorectomy or mastectomy without a full understanding of how they will affect their sexuality and other aspects of their lives.
Debu Tripathy on Using Breast Cancer Tumor DNA to Make Treatment DecisionsJuly 22nd 2016
Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at University of Texas MD Anderson Cancer Center, discusses the potential for using breast cancer tumor DNA to make treatment decisions.
Why BRCA Testing Is So Important for Women With Ovarian CancerJuly 1st 2016
National guidelines recommend that women with a personal history of ovarian cancer be tested for the BRCA mutation. Approximately 1.3% of women will develop ovarian cancer, according to the National Cancer Institute, but that risk increases to an estimated 39% in women with the BRCA1 mutation and 11% to 17% in women who inherit the BRCA2 mutation.
Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest RadiationApril 21st 2016
Chest radiation to treat a pediatric cancer is a well-known risk factor for getting breast cancer in adulthood, and research has now unearthed two specific genetic variants which may help to identify those survivors who are most at risk.